Novocure Ltd. has announced plans to file for regulatory approval for its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic adenocarcinoma based on the results of the Phase 3 PANOVA-3 trial. The filings are expected to occur in the second half of 2025 in the United States, with subsequent submissions planned for the European Union, Japan, and other key markets. The PANOVA-3 trial demonstrated that TTFields therapy, when used in conjunction with gemcitabine and nab-paclitaxel, provided a significant improvement in overall survival for patients. The results were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the Journal of Clinical Oncology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.